Fig. 2

Eplerenone reduces systemic blood pressure without direct effects on RV structure and function upon PAB. Eplerenone therapy normalizes RV mineralocorticoid receptor gene expression (MR expression, percentage of sham; a without affecting RV hypertrophy (RV/BW, mg/g; b RV systolic pressure (RVSP, mmHg; c or cardiac output (ml∙min^− 1, d while systemic blood pressure (systemic BP, mmHg; e dropped down significantly. Representative pressure-volume loops with lined end-systolic elastances (f). Quantification of end-systolic elastance (Ees, mmHg∙μl; g), echocardiography-derived RV internal diameter (RVID, mm; h) and Tricuspid annular plane systolic excursion (TAPSE, mm; i) reveal no difference between PAB and Eplerenone treated mice. n = 5–7 mice per group; *: p < 0.05 vs. cntrl; †: p < 0.05 vs. PAB